Résumé :
|
[BDSP. Notice produite par INIST-CNRS R0xItbky. Diffusion soumise à autorisation]. Laboratory studies suggest that insulin-like growth factor I (IGF-I) promotes prostatic growth. The authors evaluated the association between benign prostatic hyperplasia and IGF-I and its binding protein IGFBP-3 in community-dwelling men to determine whether this laboratory finding is manifest at the population level. Participants (n=471) were Olmsted County, Minnesota, Caucasian males aged 40-79 years in 1990. Urologic measures were assessed from the International Prostate Symptom Score, peak urinary flow rates, prostate volume, and serum prostate-specific antigen (PSA), and serum IGF-I and IGFBP-3 levels were measured. After adjustment for age, the relative odds (odds ratios) of an abnormal urologic measure in men with high versus low serum IGF-I levels were 0.98 (95% confidence interval (Cl) : 0.66,1.45) for a symptom score of>7,1.14 (95% CI : 0.72,1.80) for a peak urinary flow rate of<12 ml/second, 1.11 (95% CI : 0.72,1.72) for a prostate volume of>30 ml, and 0.71 (95% Cl : 0.46,1.09) for a PSA level of>1.4 ng/ml. A low IGFBP-3 level was associated with an enlarged prostate (odds ratio=1.72,95% Cl : 1.05,2.82), after simultaneous adjustment for IGF-I and age, but not with other urologic measures. These data do not provide evidence for an association between benign prostatic hyperplasia and serum IGF-I.
|